ICCC

ImmuCell Corporation

$10.26

0.39%
SectorHealthcareIndustryBiotechnologyCountryUnited States

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors.

Source: Yahoo Finance
AI summary

Price & performance

1M+7.5%
3M-5.5%
YTD+79.4%
1Y+72.4%
52-week range—
Beta0.27
Full chart and returns against a benchmark

Q-Score

75/ 100

Quality against peers; 50 is the peer median.

Growth63
Risk72
Performance65
Valuation68
Profitability66
Leverage59
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$27.6M+4.3%
Net income-$1M
Net margin-3.8%+4.4 pts
Historical fundamentals

Red flags in filings

1active red flag
Material impairmentJan 8, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Largest customer72%
Regions, segments, customers and suppliers

Valuation

ICCCIndustryP/E118.3589.69P/S3.0411.88EV/EBITDA14.7467.10P/B2.976.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report, after the close
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate